The stock of Lantheus Holdings Inc (NASDAQ:LNTH) is a huge mover today! The stock last traded at $9.1 per share. It is down 343.90% since April 28, 2016 and is uptrending. It has outperformed by 337.98% the S&P500.
The move comes after 9 months positive chart setup for the $320.12M company. It was reported on Dec, 1 by Barchart.com. We have $9.92 PT which if reached, will make NASDAQ:LNTH worth $28.81M more.
Analysts await Lantheus Holdings Inc (NASDAQ:LNTH) to report earnings on February, 27. They expect $0.13 EPS, 0.00% or $0.00 from last year’s $0.13 per share. LNTH’s profit will be $4.57M for 17.50 P/E if the $0.13 EPS becomes a reality. After $0.15 actual EPS reported by Lantheus Holdings Inc for the previous quarter, Wall Street now forecasts -13.33% negative EPS growth.
Lantheus Holdings Inc (NASDAQ:LNTH) Ratings Coverage
Out of 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Lantheus Holdings has been the topic of 9 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Credit Suisse initiated it with “Neutral” rating and $8 target price in Friday, September 23 report. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) has “Buy” rating given on Monday, August 29 by Jefferies. RBC Capital Markets maintained Lantheus Holdings Inc (NASDAQ:LNTH) on Wednesday, February 24 with “Outperform” rating. The stock has “Neutral” rating given by Robert W. Baird on Monday, August 31. The firm has “Neutral” rating by Credit Suisse given on Friday, December 11. Wells Fargo downgraded the shares of LNTH in a report on Wednesday, September 30 to “Market Perform” rating.
According to Zacks Investment Research, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.”
More important recent Lantheus Holdings Inc (NASDAQ:LNTH) news were published by: Fool.com which released: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” on November 16, 2016, also Fool.com published article titled: “Why Lantheus Holdings Inc. Sold Lower Friday”, Businesswire.com published: “Lantheus Holdings, Inc. Announces Upsize of Public Offering to 3500000 Shares …” on November 16, 2016. More interesting news about Lantheus Holdings Inc (NASDAQ:LNTH) was released by: Businesswire.com and their article: “Lantheus Holdings, Inc. Announces Public Offering of 5200000 Shares of Common …” with publication date: September 08, 2016.
LNTH Company Profile
Lantheus Holdings, Inc., incorporated on November 30, 2007, develops, makes and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.